CRT In The News

Curis Announces FDA Approval of Erivedge (vismodegib) Capsule as First Treatment for Advanced BCC - January 30 2012
Call for Reagents - December 15 2011
Stephen Friend visits CRT to discuss Arch2POCM - December 15 2011
FEATURE: CCR4 - from target discovery to a license and sponsored collaboration with Affitech - December 15 2011
FEATURE: Successful Discovery Committee grant application shows promise for novel drug combinations - December 15 2011
FEATURE: CRT reflects on a successful NCRI conference - December 15 2011
CRT’s Discovery Laboratory Autotaxin programme progresses to Lead Optimisation - September 01 2011
Preclinical Development Candidate selected for Chk1 Inhibitor Programme - August 19 2011
FEATURE: CRT pioneers new ways of generating exciting research and licensing discoveries - July 28 2011
FEATURE: BliNK Therapeutics, our 24th spin-out company is formed - July 28 2011
FEATURE: Abiraterone receives approval from FDA to be marketed as a prostate cancer therapy - Zytiga - July 28 2011
New Type of Hormone Therapy Extends Prostate Cancer Patients’ Lives, Study Finds - May 25 2011
Positive Results in Genentech Ph II Clinical Trial of GDC-0449 in Advanced Basal Cell Carcinoma - March 21 2011
Biothera acquires MUC1 anti-cancer monoclonal antibody from Antisoma - March 10 2011
Working to develop a new HPV vaccine - November 23 2010
We are moving - November 23 2010
CRT drives novel and collaborative drug discovery in areas of “hot” cancer science - November 23 2010
Maximising our global network - November 23 2010
Temodar® patent enforcement case won - November 06 2010
Oxford BioMedica announces amendment to 5T4 licence agreement with CRT and issue of shares - June 18 2010

‹ Older Articles

© Cancer Research Technology 2012